Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborator:

AbbVie

Information provided by (Responsible Party):

Bristol-Myers Squibb

ClinicalTrials.gov Identifier:

NCT01239797

First received: November 8, 2010

Last updated: May 10, 2016

Last verified: April 2016

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	March 2018
Primary Completion Date:	September 2014 (Final data collection date for primary outcome measure)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):